SG11201702574XA - Use of neridronic acid or of its salt for the treatment of osteoarthrosis - Google Patents

Use of neridronic acid or of its salt for the treatment of osteoarthrosis

Info

Publication number
SG11201702574XA
SG11201702574XA SG11201702574XA SG11201702574XA SG11201702574XA SG 11201702574X A SG11201702574X A SG 11201702574XA SG 11201702574X A SG11201702574X A SG 11201702574XA SG 11201702574X A SG11201702574X A SG 11201702574XA SG 11201702574X A SG11201702574X A SG 11201702574XA
Authority
SG
Singapore
Prior art keywords
osteoarthrosis
salt
treatment
neridronic acid
neridronic
Prior art date
Application number
SG11201702574XA
Inventor
Varenna Massimo
Original Assignee
Abiogen Pharma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51904075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201702574X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abiogen Pharma Spa filed Critical Abiogen Pharma Spa
Publication of SG11201702574XA publication Critical patent/SG11201702574XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201702574XA 2014-10-15 2015-10-15 Use of neridronic acid or of its salt for the treatment of osteoarthrosis SG11201702574XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI20141794 2014-10-15
PCT/IB2015/057929 WO2016059594A1 (en) 2014-10-15 2015-10-15 Use of neridronic acid or of its salt for the treatment of osteoarthrosis

Publications (1)

Publication Number Publication Date
SG11201702574XA true SG11201702574XA (en) 2017-04-27

Family

ID=51904075

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201702574XA SG11201702574XA (en) 2014-10-15 2015-10-15 Use of neridronic acid or of its salt for the treatment of osteoarthrosis

Country Status (32)

Country Link
US (2) US20170209470A1 (en)
EP (1) EP3206694B1 (en)
JP (1) JP6839076B2 (en)
KR (1) KR102591084B1 (en)
CN (2) CN111939164A (en)
AU (1) AU2015332060B2 (en)
BR (1) BR112017006989A2 (en)
CA (1) CA2963066C (en)
CL (1) CL2017000915A1 (en)
CO (1) CO2017003561A2 (en)
CY (1) CY1123420T1 (en)
DK (1) DK3206694T3 (en)
DO (1) DOP2017000096A (en)
EA (1) EA033191B1 (en)
EC (1) ECSP17023093A (en)
ES (1) ES2819186T3 (en)
HR (1) HRP20201475T1 (en)
HU (1) HUE052088T2 (en)
IL (1) IL251421B (en)
LT (1) LT3206694T (en)
MX (1) MX2017004826A (en)
MY (1) MY191481A (en)
NZ (1) NZ730853A (en)
PE (1) PE20170699A1 (en)
PH (1) PH12017500659A1 (en)
PL (1) PL3206694T3 (en)
PT (1) PT3206694T (en)
RS (1) RS60868B1 (en)
SG (1) SG11201702574XA (en)
SI (1) SI3206694T1 (en)
TN (1) TN2017000095A1 (en)
WO (1) WO2016059594A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190328755A1 (en) * 2018-04-30 2019-10-31 Grunenthal Gmbh Methods of treating complex regional pain syndrome (crps) or symptoms comprising administration of neridronic acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20040218A1 (en) * 2004-02-10 2004-05-10 Abiogen Pharma Spa USE OF SODIUM NERHYDRONATE TO PROMOTE BONE NEOFORMATION
CA2565079A1 (en) * 2004-05-06 2005-11-17 Merck & Co., Inc. Methods for treating arthritic conditions in dogs
EP1988907A4 (en) * 2006-02-06 2010-04-14 Cypress Bioscience Inc Compositions comprising a bisphosphonate and an antifolate
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate

Also Published As

Publication number Publication date
AU2015332060B2 (en) 2018-06-07
CY1123420T1 (en) 2021-12-31
PE20170699A1 (en) 2017-06-03
US20230233585A1 (en) 2023-07-27
CN106794190A (en) 2017-05-31
LT3206694T (en) 2020-11-25
CA2963066A1 (en) 2016-04-21
EA033191B1 (en) 2019-09-30
ECSP17023093A (en) 2017-06-30
EA201790531A1 (en) 2017-08-31
SI3206694T1 (en) 2020-11-30
KR20170066438A (en) 2017-06-14
AU2015332060A1 (en) 2017-04-27
EP3206694A1 (en) 2017-08-23
WO2016059594A1 (en) 2016-04-21
US20170209470A1 (en) 2017-07-27
JP6839076B2 (en) 2021-03-03
IL251421B (en) 2022-05-01
JP2017532333A (en) 2017-11-02
MY191481A (en) 2022-06-28
RS60868B1 (en) 2020-11-30
DOP2017000096A (en) 2017-07-31
PL3206694T3 (en) 2020-12-28
HUE052088T2 (en) 2021-04-28
MX2017004826A (en) 2018-01-24
TN2017000095A1 (en) 2018-07-04
NZ730853A (en) 2018-06-29
IL251421A0 (en) 2017-05-29
CO2017003561A2 (en) 2017-09-11
KR102591084B1 (en) 2023-10-18
EP3206694B1 (en) 2020-07-08
PH12017500659A1 (en) 2017-10-02
DK3206694T3 (en) 2020-09-21
CN111939164A (en) 2020-11-17
ES2819186T3 (en) 2021-04-15
BR112017006989A2 (en) 2018-03-27
CL2017000915A1 (en) 2017-11-10
PT3206694T (en) 2020-09-22
CA2963066C (en) 2023-12-05
HRP20201475T1 (en) 2020-12-11

Similar Documents

Publication Publication Date Title
IL253945A0 (en) Kdm1a inhibitors for the treatment of disease
HK1232147A1 (en) Cenicriviroc for the treatment of fibrosis
IL250960B (en) Cenicriviroc combination therapy for the treatment of fibrosis
IL252873A0 (en) L-tartrate salt of pridopidine
EP3180009A4 (en) Zoledronic acid dosage forms for the treatment of pain
ZA201608843B (en) Chloride salt of tat-nr2b9c
SG11201604954YA (en) Novel tetrahydropyridopyrimidine compound or salt thereof
IL249502A0 (en) Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies
HK1222794A1 (en) Methods for the prevention or treatment of left ventricle remodeling
SG11201702700UA (en) Methods for the treatment of peri-implantitis
IL259073A (en) 3'-substituted-abscisic acid derivatives
PT3340975T (en) Formulation for the treatment of acne
IL251421B (en) Use of neridronic acid or of its salt for the treatment of osteoarthrosis
EP3145525A4 (en) Use of microperoxidases for the treatment of carboxyhemoglobinemia
GB201412010D0 (en) Treatment of hypertransaminasemia